Spinal News International e-newsletter

Главная  /  Новости  /  Spinal News International e-newsletter

BIBA Publishing message

 Click here to view web version

 Friday, 20 April 2018

 Top stories

 First dynamic spine brace—the robotic spine exoskeleton—characterises spinal deformities

 Designed by Columbia Engineers, the robotic spine exoskeleton (RoSE) is the first device to take in vivo measurements of torso stiffness and to characterise the three dimensional stiffness of the human torso. RoSE could lead to new treatments for children with spinal deformities such as idiopathic scoliosis and kyphosis, according to lead investigators of the study, published online in the journal IEEE Transactions of Neural Systems and Rehabilitation Engineering.

 Neurokinex Kids paediatric rehabilitation facility opens in Crawley, UK

 Neurokinex—the first and only international community fitness and wellness affiliate of the Christopher and Dana Reeve Foundation’s NeuroRecovery Network (NRN)—has opened Neurokinex Kids to help children living with paralysis. This Gatwick-based facility provides children in the UK with rehabilitation therapies; a combination of utilising scientific research on brain and spinal cord plasticity, and activity-based interventions designed to achieve greater motor and autonomic recoveries.

 Belgian surgeon Marek Szpalski named ISASS president 2018–2019

 The International Society for the Advancement of Spine Surgery (ISASS) named Belgian surgeon Marek Szpalski (Iris South Hospitals/Molière Longchamp, Brussels, Belgium) society president for the year 2018–2019 at their annual conference last week (10–13 April, Toronto, Canada). Szpalski is taking over the role from Jeffrey A Goldstein (NYU Langone Medical Center Hospital for Joint Diseases, New York, USA).

 Emerging Implant Technologies on target with disruptive spinal implant designs

 Frustration at the clinical shortcomings of existing cage designs and materials on the market provided the impetus for the creation of EIT Cellular Titanium. Previous market solutions were inappropriate for fusion, and had issues of biocompatibility, subsidence, migration and imaging distortion. To improve in all of these areas, a proven, bonefriendly material in a specific configuration was needed and EIT Cellular Titanium was developed.This article is sponsored by EIT.

 Advancing spinal surgery with 3D-printed Tritanium implants “engineered for bone”

 Stryker’s 3D-printed Tritanium In-Growth Technology continues to impact spinal surgery. A novel, highly porous titanium material designed for bone in-growth and biological fixation, Tritanium was first introduced to spinal surgeons in 2016 when Stryker’s Spine division launched the Tritanium Posterior Lumbar (PL) Cage used in lumbar interbody fusion procedures for skeletally mature patients with degenerative disc disease and other conditions. This article is sponsored by Stryker.

 Preclinical studies of a non-invasive cell therapy for DDD highlight its safety and efficacy

 Two preclinical studies of IDCT, an allogenic (donor-derived), non-invasive cell therapy for the treatment of degenerative disc disease (DDD), demonstrate that proprietary discogenic cells, the active ingredient of IDCT, are safe and non-tumor forming. DiscGenics, a clinical stage regenerative medicine company developing cell therapies for patients with mild to moderate DDD, announced these results at the Orthopaedic Research Society (ORS) 2018 Annual Meeting (10–13 March, New Orleans, USA).

 Events

 26–27 April

 EUROSPINE Spring Speciality Meeting

 Vienna, Austria

 27–28 April

 Emerging Technologies in Spine Surgery

 Burr Ridge, USA

 04–05 May

 Minimally Invasive Spine Surgery with Radiation Reducing Techniques

 Burr Ridge, USA

 Write to us:

 Editor: Suzie Marshall - suzie@bibamedical.com

 Advertise with us:

 Elizabeth Sutherst - elizabeth@bibamedical.com

 You are receiving this email because you subscribed/registered on www.spinalnewsinternational.com

 Our mailing address is:

 BIBA Medical Ltd,
 526 Fulham Road, Fulham, London, SW6 5NR

 TEL: +44 (0)20 7736 8788

 FAX: +44 (0)20 7736 8283